Aton (ALTAO.PA) Stock Price

Aton Price

Euronext·CLOSED
0.01EUR-0.0002 (-1.94 %)
Market closed

Revenue at Aton has contracted by 8.9% per year over the past 19 years to 614,000.00 EUR. For Aton, the net margin of -179.3% is up versus -313.1% a few years ago. The stock trades about 96% above its 52-week low.

Aton stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Aton over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Aton stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Aton's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Aton Stock Price History
DateAton Price
7/31/20260.01 EUR
7/30/20260.01 EUR
7/29/20260.01 EUR
7/28/20260.01 EUR
7/27/20260.01 EUR
7/24/20260.01 EUR
7/23/20260.01 EUR
7/22/20260.01 EUR
7/21/20260.01 EUR
7/20/20260.01 EUR
7/17/20260.01 EUR
7/15/20260.01 EUR
7/14/20260.01 EUR
7/13/20260.01 EUR
7/10/20260.01 EUR
7/9/20260.01 EUR
7/8/20260.01 EUR
7/7/20260.01 EUR
7/6/20260.01 EUR
7/3/20260.01 EUR
7/2/20260.01 EUR
7/1/20260.01 EUR
6/30/20260.01 EUR
6/29/20260.01 EUR
6/26/20260.01 EUR
6/25/20260.01 EUR
6/24/20260.01 EUR
6/23/20260.01 EUR
6/22/20260.01 EUR
6/19/20260.01 EUR
6/18/20260.01 EUR
6/17/20260.01 EUR
6/16/20260.01 EUR
6/15/20260.01 EUR
6/12/20260.01 EUR
6/11/20260.01 EUR
6/10/20260.01 EUR
6/9/20260.01 EUR
6/8/20260.01 EUR
6/5/20260.01 EUR
6/4/20260.01 EUR
6/3/20260.01 EUR
6/2/20260.01 EUR
6/1/20260.01 EUR
5/29/20260.02 EUR
5/28/20260.01 EUR
5/27/20260.01 EUR
5/26/20260.01 EUR
5/25/20260.01 EUR
5/22/20260.01 EUR
5/21/20260.01 EUR
5/20/20260.01 EUR
5/19/20260.01 EUR
5/18/20260.02 EUR
5/15/20260.02 EUR
5/14/20260.02 EUR
5/13/20260.02 EUR
5/12/20260.02 EUR
5/11/20260.02 EUR
5/8/20260.02 EUR
5/7/20260.01 EUR
5/6/20260.02 EUR
5/5/20260.01 EUR
5/4/20260.02 EUR
4/30/20260.01 EUR
4/29/20260.01 EUR
4/28/20260.02 EUR
4/27/20260.02 EUR
4/24/20260.01 EUR
4/23/20260.01 EUR
4/22/20260.01 EUR
4/21/20260.01 EUR
4/20/20260.01 EUR
4/17/20260.01 EUR
4/16/20260.01 EUR
4/15/20260.01 EUR
4/14/20260.01 EUR
4/13/20260.01 EUR
4/10/20260.01 EUR
4/9/20260.01 EUR
4/8/20260.01 EUR
4/7/20260.01 EUR
4/2/20260.01 EUR
3/27/20260.01 EUR
3/26/20260.01 EUR
3/25/20260.01 EUR
3/24/20260.01 EUR
3/23/20260.01 EUR
3/20/20260.01 EUR
3/19/20260.01 EUR
3/18/20260.01 EUR
3/16/20260.01 EUR
3/13/20260.01 EUR
3/12/20260.01 EUR
3/11/20260.01 EUR
3/10/20260.01 EUR
3/9/20260.01 EUR
3/6/20260.01 EUR
3/5/20260.01 EUR
3/4/20260.01 EUR
2/25/20260.01 EUR
2/24/20260.01 EUR
2/23/20260.01 EUR
2/20/20260.01 EUR
2/19/20260.01 EUR
2/18/20260.01 EUR
2/17/20260.01 EUR
2/16/20260.01 EUR
2/13/20260.01 EUR
2/12/20260.01 EUR
2/11/20260.01 EUR
2/10/20260.01 EUR
2/9/20260.01 EUR
2/6/20260.01 EUR
2/5/20260.01 EUR
2/4/20260.01 EUR
2/3/20260.01 EUR
2/2/20260.01 EUR
1/30/20260.01 EUR
1/29/20260.01 EUR
1/28/20260.01 EUR
1/27/20260.01 EUR
1/26/20260.01 EUR
1/23/20260.01 EUR
1/22/20260.01 EUR
1/21/20260.01 EUR
1/20/20260.01 EUR
1/19/20260.01 EUR
1/16/20260.01 EUR
1/15/20260.01 EUR
1/14/20260.01 EUR
1/13/20260.01 EUR
1/12/20260.01 EUR
1/9/20260.01 EUR
1/8/20260.01 EUR
1/7/20260.01 EUR
1/6/20260.01 EUR
1/5/20260.01 EUR
1/2/20260.01 EUR
12/31/20250.01 EUR
12/30/20250.01 EUR
12/29/20250.01 EUR
12/24/20250.01 EUR
12/23/20250.01 EUR
12/22/20250.01 EUR
12/19/20250.01 EUR
12/18/20250.01 EUR
12/17/20250.01 EUR
12/16/20250.01 EUR
12/15/20250.01 EUR
12/12/20250.01 EUR
12/11/20250.01 EUR
12/10/20250.01 EUR
12/9/20250.01 EUR
12/8/20250.01 EUR
12/5/20250.01 EUR
12/4/20250.01 EUR
12/3/20250.01 EUR
12/2/20250.01 EUR
12/1/20250.01 EUR
11/28/20250.01 EUR
11/27/20250.01 EUR
11/26/20250.01 EUR
11/25/20250.01 EUR
11/24/20250.01 EUR
11/21/20250.01 EUR
11/20/20250.01 EUR
11/19/20250.01 EUR
11/18/20250.01 EUR
11/17/20250.01 EUR
11/14/20250.01 EUR
11/13/20250.01 EUR
11/12/20250.01 EUR
11/11/20250.01 EUR
11/10/20250.01 EUR
11/7/20250.01 EUR
11/6/20250.01 EUR
11/5/20250.01 EUR
11/4/20250.01 EUR
11/3/20250.01 EUR
10/31/20250.01 EUR
10/30/20250.01 EUR
10/29/20250.01 EUR
10/28/20250.01 EUR
10/27/20250.01 EUR
10/24/20250.01 EUR
10/23/20250.01 EUR
10/22/20250.01 EUR
10/21/20250.01 EUR
10/20/20250.01 EUR
10/17/20250.01 EUR
10/16/20250.01 EUR
10/15/20250.01 EUR
10/14/20250.01 EUR
10/13/20250.01 EUR
10/10/20250.01 EUR
10/9/20250.01 EUR
10/8/20250.01 EUR
10/7/20250.01 EUR
10/6/20250.01 EUR
10/3/20250.01 EUR
10/2/20250.01 EUR
10/1/20250.01 EUR
9/30/20250.01 EUR
9/29/20250.01 EUR
9/26/20250.01 EUR
9/25/20250.01 EUR
9/24/20250.01 EUR
9/23/20250.01 EUR
9/22/20250.01 EUR
9/19/20250.01 EUR
9/18/20250.01 EUR
9/17/20250.01 EUR
9/16/20250.01 EUR
9/15/20250.01 EUR
9/12/20250.01 EUR
9/11/20250.01 EUR
9/10/20250.01 EUR
9/9/20250.01 EUR
9/8/20250.01 EUR
9/5/20250.01 EUR
9/4/20250.01 EUR
9/3/20250.01 EUR
9/2/20250.01 EUR
9/1/20250.01 EUR
8/29/20250.01 EUR
8/28/20250.01 EUR
8/27/20250.01 EUR
8/26/20250.01 EUR
8/25/20250.01 EUR
8/22/20250.01 EUR
8/21/20250.01 EUR
8/20/20250.01 EUR
8/19/20250.01 EUR
8/18/20250.01 EUR
8/15/20250.01 EUR
8/14/20250.01 EUR
8/13/20250.01 EUR
8/12/20250.01 EUR
8/11/20250.01 EUR
8/8/20250.01 EUR
8/7/20250.01 EUR
8/6/20250.01 EUR
8/5/20250.01 EUR
Access this data via the Eulerpool API
Get Free API Key

Aton Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
0.00 EUR
-7.38 M EUR
-7.96 M EUR
Jan 1, 2018
77,000.00 EUR
-7.64 M EUR
-7.53 M EUR
Jan 1, 2019
234,900.00 EUR
-1.36 M EUR
-735,500.00 EUR
Jan 1, 2020
-100.00 EUR
-317,100.00 EUR
-326,700.00 EUR
Jan 1, 2021
0.00 EUR
-123,300.00 EUR
-69,200.00 EUR
Jan 1, 2022
1,600.00 EUR
-590,200.00 EUR
-563,600.00 EUR
Jan 1, 2023
612,000.00 EUR
-2.43 M EUR
-7.87 M EUR
Jan 1, 2024
614,000.00 EUR
-560,000.00 EUR
-1.10 M EUR

Aton Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 4, 2026, 10:15 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
2009201020112012201320142015201620172018201920202021202220232024
4.004.006.004.004.005.001.001.00––––––––
––50.00-33.33–25.00-80.00–––––––––
100.0075.00100.0025.00100.0020.00100.00100.00––––––––
4.003.006.001.004.001.001.001.001.001.001.001.001.001.001.001.00
-4.00-4.00-2.00-3.00-2.00-2.00-4.00-4.00-7.00-7.00-1.00–––-2.00–
-100.00-100.00-33.33-75.00-50.00-40.00-400.00-400.00––––––––
-4.00-4.00-2.00-2.00-1.00-2.00-4.00-5.00-7.00-7.00––––-7.00-1.00
-33.33–-50.00–-50.00100.00100.0025.0040.00––––––-85.71
11.9612.8913.8118.8323.4226.7235.3437.0046.7546.75233.77233.77261.25273.74299.60584.52
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Aton generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Aton retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Aton's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Aton has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Aton's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Aton stock margins

The Aton margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aton. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aton.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
79.97 %
- %
- %
Jan 1, 2018
59.74 %
-9,919.48 %
-9,776.62 %
Jan 1, 2019
99.49 %
-579.23 %
-313.11 %
Jan 1, 2020
79.97 %
317,100.00 %
326,700.00 %
Jan 1, 2021
79.97 %
- %
- %
Jan 1, 2022
-23,187.50 %
-36,887.50 %
-35,225.00 %
Jan 1, 2023
73.20 %
-397.71 %
-1,285.78 %
Jan 1, 2024
79.97 %
-91.21 %
-179.32 %

Aton Stock Revenue, EBIT, Earnings per Share

The Aton earnings per share therefore indicates how much revenue Aton has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2017
0.00 EUR
-0.16 EUR
-0.17 EUR
Jan 1, 2018
0.00 EUR
-0.16 EUR
-0.16 EUR
Jan 1, 2019
0.00 EUR
-0.01 EUR
-0.00 EUR
Jan 1, 2020
-0.00 EUR
-0.00 EUR
-0.00 EUR
Jan 1, 2021
0.00 EUR
-0.00 EUR
-0.00 EUR
Jan 1, 2022
0.00 EUR
-0.00 EUR
-0.00 EUR
Jan 1, 2023
0.00 EUR
-0.01 EUR
-0.03 EUR
Jan 1, 2024
0.00 EUR
-0.00 EUR
-0.00 EUR

Aton business model & stock analysis

Hybrigenics SA is a French company that was founded in 1997 to develop innovative technologies for the discovery and development of new drugs. The company specializes in the identification of proteins responsible for the development of cancer and other diseases, as well as the development of therapies for these diseases. It is headquartered in Paris and has branches in the United States and Japan. Hybrigenics has become a leading provider of protein research technologies since its founding, employing approximately 50 employees including scientists, engineers, and technicians. The company's business model is based on developing innovative technologies for drug discovery and development. It conducts research and development in the field of protein research, particularly protein interaction analysis. The company aims to better understand the mechanism of action of proteins involved in disease development in order to develop targeted therapies. Hybrigenics collaborates closely with its customers to develop tailored solutions for their specific research needs. It provides a range of products and services including proteomic services, screening tools, data analysis software, and platform technologies. The company is divided into different divisions, including proteomic services, screening tools, data analysis software, and platform technologies. Some of the key divisions include proteomic services, which offer customers proteomic services based on decades of experience in protein research and analysis. These services allow customers to identify new proteins involved in specific diseases and also provide protein interaction analysis services to better understand the mechanism of action of disease proteins. Hybrigenics offers screening tools that allow customers to quickly and easily investigate and compare different proteins. These tools are particularly useful for identifying proteins that can serve as indicators for specific diseases. The company also offers data analysis software that enables customers to quickly and accurately evaluate the results of their protein research. This software uses algorithms and artificial intelligence to analyze data and identify patterns. Hybrigenics has also developed a range of platform technologies to help customers optimize their protein research. These technologies include the yeast two-hybrid assay, which can be used to study protein interactions, as well as various technologies for protein expression and purification. Hybrigenics offers a variety of products tailored to its different divisions. Some of the key products include the PIII-Toolbox, a comprehensive platform technology for protein research that allows for fast and efficient identification of protein-protein interactions, HybriScreen Plus, a screening tool that helps customers quickly and easily investigate and compare different proteins, and the yeast two-hybrid assay, a platform technology for studying protein interactions to better understand the mechanism of action of disease proteins.

Aton SWOT Analysis

Strengths

Hybrigenics SA possesses robust research and development capabilities, allowing them to innovate and develop cutting-edge biotechnology products and solutions.

The company holds a substantial intellectual property portfolio, which provides them with a competitive advantage and facilitates protection of their innovative technologies and discoveries.

Hybrigenics SA has built a strong brand reputation in the biotechnology industry through their quality products, reliable services, and successful collaborations.

With a global presence, Hybrigenics SA has access to diverse markets worldwide, enabling them to tap into various opportunities and reach a wide customer base.

Weaknesses

The company's revenue is highly dependent on a few key customers, which poses a risk if any of these customers reduce their purchases or choose to work with competitors.

Hybrigenics SA has a relatively limited range of products and services, which may restrict their ability to cater to diverse customer demands and limit revenue generation.

Opportunities

The increasing global demand for biotechnology products presents a significant opportunity for Hybrigenics SA to expand their market presence and capitalize on the growing industry.

Forming strategic partnerships and collaborations with other leading companies or research institutions can enhance Hybrigenics SA's research capabilities, diversify their product offering, and increase market penetration.

Threats

The biotechnology industry is highly competitive, with numerous established players and emerging startups. Hybrigenics SA faces the risk of losing market share to competitors who may offer similar or more innovative solutions.

Adhering to complex regulatory frameworks, obtaining necessary approvals, and ensuring compliance with evolving industry regulations pose challenges and may impact Hybrigenics SA's operations and product development timeline.

Aton Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Aton historical P/E ratio, EBIT multiple, and P/S ratio

Aton annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Aton shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2017
46.75 M Stocks
Jan 1, 2018
46.75 M Stocks
Jan 1, 2019
233.77 M Stocks
Jan 1, 2020
233.77 M Stocks
Jan 1, 2021
261.25 M Stocks
Jan 1, 2022
273.74 M Stocks
Jan 1, 2023
299.60 M Stocks
Jan 1, 2024
584.52 M Stocks
Price targets and forecasts for Aton are not yet available.

Aton shareholder structure

% Name
28.95123%
Evangelista (Fabrice)
Evangelista (Fabrice)
14.04275%
Vatel Capital S.A.S.
Vatel Capital S.A.S.
8.18720%
Diagnostic Medical Systems SA
Diagnostic Medical Systems SA
5.61952%
Famille Ansel
Famille Ansel
3.65031%
Eftekhari (Pierre Ph.D.)
Eftekhari (Pierre Ph.D.)
0.21902%
Atayi (Leone)
Atayi (Leone)

Aton Beneficial Ownership Filings (SEC 13D/G)

Free Float
31.8%
Float Shares
-
Shares Outstanding
-

Aton Executives and Management Board

5 members · 40 % women

AA

Ms. Ayikoele Atayi

Chairman of the Board, Chief Executive Officer · since 2022

47,500.00 EUR

EB

Mr. Enrico Bastianelli

Independent Director

200,000.00 EUR
PE

Dr. Pierre Eftekhari

Director

–
HL

Mr. Hadrien Lanvin

Independent Director

–
VM

Ms. Virginie Miath

Independent Director

–

Frequently asked questions about Aton

Hybrigenics SA is a biopharmaceutical company specializing in research and development of innovative cancer treatments. Their business model focuses on the discovery and development of targeted therapies, using a unique technology called "protein interactions," which enables the identification of novel therapeutic targets. By leveraging their expertise in protein sciences and oncology, Hybrigenics aims to advance the understanding of cancer biology and contribute to the development of effective and personalized cancer treatments. With a strong emphasis on scientific excellence, Hybrigenics is dedicated to discovering breakthrough therapies that can significantly impact the lives of cancer patients worldwide.

Hybrigenics SA is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Hybrigenics SA in the market include pharmaceutical and biotechnology companies such as Genmab, Celgene Corporation, and Novartis AG.

Hybrigenics SA is a French biopharmaceutical company with a rich history and background. Established in 1997, Hybrigenics focuses on identifying and developing innovative treatments for various diseases, particularly in the field of oncology. It has built expertise in protein interactions and developed the UniTrap technology for high-throughput yeast two-hybrid screenings. Over the years, the company has achieved significant milestones, including the discovery of inecalcitol, a potential therapeutic agent for acute myeloid leukemia (AML). Hybrigenics SA continues to advance research and development efforts, leveraging its scientific capabilities and collaborations to discover novel drug candidates and address unmet medical needs.

Hybrigenics SA, a leading biopharmaceutical company, has achieved several significant milestones. One notable achievement is the successful completion of Phase II clinical trials for its innovative drug candidate, Inecalcitol, in patients with acute myeloid leukemia. Additionally, Hybrigenics SA has formed strategic partnerships with renowned pharmaceutical companies, facilitating the advancement of its drug development programs. The company's dedication to research and development is demonstrated by its numerous patent filings and scientific publications. Moreover, Hybrigenics SA's strong commitment to expanding its global reach is evident through the establishment of subsidiaries in the United States and the opening of international offices.

Hybrigenics SA is primarily present in France, with its headquarters located in Paris. As a biopharmaceutical company, Hybrigenics SA focuses on research and development in the field of oncology. With a strong presence in France, Hybrigenics SA conducts its operations and collaborates with various institutions, universities, and research centers within the country. Its commitment to advancing scientific knowledge and therapeutic solutions has established Hybrigenics SA as a prominent player in the French biotechnology industry.

Hybrigenics SA represents strong values and a distinct corporate philosophy. The company prides itself on innovation, commitment to scientific excellence, and dedication to improving human health. Hybrigenics SA emphasizes transparency, integrity, and accountability in all its operations. Through cutting-edge research and development, the company aims to create innovative therapies and diagnostic solutions for challenging diseases. With a focus on collaboration and partnerships, Hybrigenics SA strives to make a meaningful impact in the biotechnology and pharmaceutical industries. Overall, Hybrigenics SA stands for pushing boundaries, delivering quality, and pioneering advancements in the field of life sciences.

7 analysts currently rate the Aton stock: 0 recommend buying, 2 holding and 5 selling.

Aton Analyst Price Targets 2026

The Aton share (ALTAO.PA) is listed on 4 stock exchanges, including: Frankfurt (3HB.F), München (3HB.MU), Paris (ALHYG.PA).

Hybrigenics SA is a leading biotechnology company specialized in the discovery of innovative therapies for serious diseases such as cancer, neurodegenerative diseases, and infectious diseases. The company is based in Paris, France, and employs an international team of scientists working on the development and commercialization of new drugs. Hybrigenics' business model is based on three main areas: biopharmaceutical business, service business, and research and development program. The biopharmaceutical business of Hybrigenics includes the research and development of drugs against cancer and neurodegenerative diseases. The company uses its proprietary technology platform, UbiTrap®, to specifically identify proteins related to disease development. Based on these findings, the company develops novel therapies that aim to selectively target specific disease-relevant proteins. One product that has emerged from this business area is a drug against acute myeloid leukemia (AML) called Inecalcitol. It is currently in phase IIb of clinical trials and has shown promising results. Additionally, Hybrigenics is working on the development of therapies for Parkinson's and Alzheimer's by identifying and targeting protein aggregates in a similar manner. Hybrigenics' service business includes various types of contract research services. The company offers specialized protein research services to its customers based on the UbiTrap® technology platform. Customers can submit their own proteins, and the company identifies specific interaction partners or posttranslational modifications with high specificity and sensitivity. Hybrigenics also offers network analysis to identify and characterize protein interaction partners, gaining a better understanding of the complex signaling pathways and mechanisms that cause diseases. This service is in high demand in the pharmaceutical and biotechnology industry. Lastly, Hybrigenics conducts an extensive research and development program to develop new technologies and products that could complement its existing product range. This program focuses on identifying new molecular targets that have not been previously known and optimizing existing technologies. In summary, Hybrigenics' business model aims to utilize its proprietary technology platform to identify new target molecules and develop innovative therapies against cancer and neurodegenerative diseases. The company complements these activities with a wide range of services targeting pharmaceutical and biotech companies, including the identification of protein modifications and network analysis. With a strong focus on research and development, Hybrigenics is well positioned to further expand its portfolio of products and services in the future.

The revenue cannot currently be calculated for Aton.

The profit cannot currently be calculated for Aton.

The P/E ratio cannot be calculated for Aton at the moment.

The P/S cannot be calculated for Aton currently.

The Eulerpool Quality Score for Aton is 3/10.

The ISIN of Aton is FR0004153930. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Aton is A0M9ZU. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Aton is ALTAO.PA. The ticker symbol is used to trade Aton shares on the stock exchange.

Aton paid dividends every year for the past 0 years.

Aton is assigned to the 'Health' sector.

The dividends of Aton are distributed in EUR.

All fundamentals and in-depth analysis of Aton

Our stock analysis for Aton stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aton. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Aton Stock
Aton Revenue→
Aton Stock
Aton Net Income→
Aton Stock
Aton P/E→
Aton Stock
Aton P/S→
Aton Stock
Aton EBIT→
Aton Stock
Aton Dividend→
Aton Stock
Aton Directors Dealings→
Aton Stock
Aton Stocks→
Aton Stock
Aton Market capitalization→
Aton Stock
Aton Debt→
Aton Stock
Aton Liabilities→
Aton Stock
Aton Equity→
Aton Stock
Aton AAQS→
Aton Stock
Aton Employees→
Aton Stock
Aton ROE→
Aton Stock
Aton ROA→
Aton Stock
Aton ROCE→
Aton Stock
Aton News→
Aton Stock
Aton Analyst Price Targets→

Health Stocks

Atossa TherapeuticsAtomo DiagnosticsAtriCureAtlas EnergyAtrys HealthAtlantic InternationalAttendo AB (publ)AthersysaTyr PharmaAthens Medical CenterAunaAtectAll Stocks A–Z →